BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 27517620)

  • 1. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An N
    Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
    Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
    Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.
    Liu YY; Patwardhan GA; Bhinge K; Gupta V; Gu X; Jazwinski SM
    Cancer Res; 2011 Mar; 71(6):2276-85. PubMed ID: 21278235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin-activated RNA methylation.
    Roy KR; Uddin MB; Roy SC; Hill RA; Marshall J; Li YT; Chamcheu JC; Lu H; Liu YY
    FASEB Bioadv; 2020 Nov; 2(11):653-667. PubMed ID: 33205006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.
    Alam SK; Yadav VK; Bajaj S; Datta A; Dutta SK; Bhattacharyya M; Bhattacharya S; Debnath S; Roy S; Boardman LA; Smyrk TC; Molina JR; Chakrabarti S; Chowdhury S; Mukhopadhyay D; Roychoudhury S
    Cell Death Differ; 2016 Apr; 23(4):707-22. PubMed ID: 26494468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
    Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
    Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
    Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
    Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 in colon cancer.
    Nakayama M; Oshima M
    J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.
    Solomon H; Dinowitz N; Pateras IS; Cooks T; Shetzer Y; Molchadsky A; Charni M; Rabani S; Koifman G; Tarcic O; Porat Z; Kogan-Sakin I; Goldfinger N; Oren M; Harris CC; Gorgoulis VG; Rotter V
    Oncogene; 2018 Mar; 37(12):1669-1684. PubMed ID: 29343849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells.
    Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH
    Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
    Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
    Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions.
    Zhang Y; Yan W; Chen X
    J Biol Chem; 2011 May; 286(18):16218-28. PubMed ID: 21454711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Expressions of CUL4A and TP53 in Colorectal Cancer Predict Poor Survival.
    Li C; Bu J; Liao Y; Zhang J; Han J; Zhang H; Xing H; Li Z; Wu H; Liang L; Wang M; Qin W; Yang T
    Cell Physiol Biochem; 2018; 51(6):2829-2842. PubMed ID: 30562757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity.
    Ye J; Wei X; Shang Y; Pan Q; Yang M; Tian Y; He Y; Peng Z; Chen L; Chen W; Wang R
    Oncogene; 2017 Nov; 36(46):6391-6407. PubMed ID: 28745318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceramide-Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations.
    Khiste SK; Liu Z; Roy KR; Uddin MB; Hosain SB; Gu X; Nazzal S; Hill RA; Liu YY
    Mol Cancer Ther; 2020 Feb; 19(2):564-574. PubMed ID: 31645443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
    Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
    Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor.
    Basak D; Punganuru SR; Srivenugopal KS
    Int J Oncol; 2016 Apr; 48(4):1426-36. PubMed ID: 26848023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.
    Chiu LY; Hsin IL; Yang TY; Sung WW; Chi JY; Chang JT; Ko JL; Sheu GT
    Oncogene; 2017 Jan; 36(2):242-253. PubMed ID: 27270426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
    Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
    Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.